Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
An AHA blog published Sept. 16 highlights programs and practices by Boston Medical Center leaders and staff that support residents’ mental health, emotional…
Headline
Susan Doherty, AHA’s vice president of field engagement, and Rebecca Chickey, AHA’s senior director of behavioral health services, write on the unique ways…
Blog
This year, the Centers for Disease Control and Prevention reported that over 49,000 people died by suicide in 2023, the latest year for which data was…
Headline
Corey Feist, CEO and co-founder of the Dr. Lorna Breen Heroes Foundation, and Tiffany Lyttle, R.N., director of cultural integration at Centra Health, discuss…
Blog
Medical residency is one of the most demanding stages in a physician’s career. Long hours, intense learning and new responsibilities often push trainees to…
Headline
A Gallup report published Sept. 9 found that nearly 48 million Americans currently have or are being treated for depression. The total, which equals 18.3% of…